Devax, Inc. Initiates Enrollment In The DIVERGE Clinical Trial With The AXXESS(TM) Drug Eluting Bifurcation Stent System

Published: Jun 21, 2006

IRVINE, Calif.--(BUSINESS WIRE)--June 20, 2006--Devax Inc. announced today the initiation of the DIVERGE clinical study for the company's AXXESS(TM) Biolimus A9(TM) Eluting Bifurcation Stent System. The first patient to receive the AXXESS stent in this study was treated by Stefan Verheye, M.D., Ph.D., co-principal investigator of the study and co-director of the Antwerp Cardiovascular Institute at the Middelheim Hospital in Antwerp, Belgium.

Back to news